Overview

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
0
Participant gender:
All
Summary
Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with trastuzumab [TC-H] or weekly paclitaxel with trastuzumab [P-H]) at the standard approved doses, aiming to gather more information regarding cost-effectiveness, toxicity, quality of life (QoL), patient reported outcomes and clinical benefits of the two treatment strategies.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Lawson Health Research Institute
London Health Sciences Centre
Collaborator:
The Ottawa Hospital
Treatments:
Albumin-Bound Paclitaxel
Cyclophosphamide
Docetaxel
Paclitaxel
Trastuzumab
Criteria
Inclusion Criteria:

- Patients with HER-2 positive early stage breast cancer for whom TC-H or weekly P-H is
being considered.

- Able to provide verbal consent.

- Willing to complete study related-questionnaires

Exclusion Criteria:

- Unable to give informed consent or complete questionnaires